Sanofi-Aventis Drug Launch Targets Mexican Obesity Crisis

Sanofi-Aventis has received a marketing authorisation for its potential blockbuster obesity treatment Acomplia (rimonabant) in Mexico, as the company continues to await approval from the US FDA. The approval gives the French multinational an opportunity to market one of its most hyped new medicines in the world's ninth-largest pharmaceutical market. But as Mexico struggles to get to grip with its current obesity epidemic, restricted state pharmaceutical coverage and limited out-of-pocket spending will likely fail to deliver the fastest-growing segment of the obesity market, Mexico's

To read the full article, please choose one of the following options: